The purpose of this research was to describe the pharmacokinetic parameters of β-hydroxyphosphocarnitine (β-HPC; CAS No. 1220955-20-3) after a single oral dose in rats and rabbits as well as to assess the impact of 14 weeks of β-HPC (100 mg/kg) treatment on the serum metabolites and liver enzymes, body weight, and hepatic steatosis of lean and obese Zucker fa/fa rats. In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively. The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h-1, respectively. In the case of the Zucker fa/fa rat study, β-HPC administered orally once a day reduced insulin, triglyceride, and cholesterol levels in the liver and serum; it also reduced weight gain and decreased liver steatosis in obese rats after 14 weeks. β-HPC could therefore potentially be used in the treatment of metabolic syndrome.

1.
Aja S, Landree LE, Kleman AM, Medghalchi SM, Vadlamudi A, McFadden JM, Aplasca A, Hyun J, Plummer E, Daniels K, Kemm M, Townsend CA, Thupari JN, Kuhajda FP, Moran TH, Ronnett GV: Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and bodyweight. Am J Physiol Regul Integr Comp Physiol 2008;294:R352-R361.
2.
Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, McClave SA: Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract 2008;23:16-34.
3.
Arduini A, Bonomini M, Savica V, Amato A, Zammit V: Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 2008;120:149-156.
4.
Ruggenenti P, Cattaneo D, Loriga G, et al: Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension 2009;54:567-574.
5.
McMackin CJ, Widlansky ME, Hamburg NM, et al: Effect of combined treatment with alpha-lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007;9:249-255.
6.
Giancaterini A, De Gaetano A, Mingrone G, et al: Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism 2000;49:704-708.
7.
Cao Y, Wang YX, Liu CJ, Wang LX, Han ZW, Wang CB: Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. Clin Invest Med 2009;32:E13-E19.
8.
Rebouche CJ: Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 2004;1033:30-41.
9.
Malaguarnera M: Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol 2012;28:166-176.
10.
Kafarski P, Lejczak B: Biological activity of aminophosphonic acids. Phosphorus Sulfur Silicon Relat Elem 1991;63:193-215.
11.
Fringuelli R, Utrilla Navarro MP, Milanese L, Bruscoli S, Schiaffella F, Riccardi C, De Simone C: Synthesis and evaluation of anti-apoptotic activity of L-carnitine cyclic analogues and amino acid derivatives. Farmaco 2004;59:271-277.
12.
Jain RJ, Williams RM: Asymmetric synthesis of (S)-(+)-carnitine and analogs. Tetrahedron 2001;57:6505-6509.
13.
Yamagishi T, Fujii K, Shibuya S, Yokomatsu T: Asymmetric synthesis of phosphonic acid analogues for acylcarnitine. Tetrahedron 2006;62:54-65.
14.
Gómez-Solís A, De la Cruz-Cordero R, Avalos-Soriano A, Duarte-Vázquez MA, Reyes-Esparza J, Rodríguez-Fragoso L: Efficacy and safety of two analogs of L-carnitine on rats made insulin resistant by a high-fructose diet. Pharmacology 2011;88:10-17.
15.
Reyes-Esparza J, Mendoza-Rivera B, De la Cruz-Cordero R, Rosado JL, Duarte-Vázquez MA, Solís MG, Vite-Vallejo O, Rodríguez-Fragoso L: Pharmacological evaluation of a β-hydroxyphosphonate analogue of L-carnitine in obese Zucker fa/fa rats. Basic Clin Pharmacol Toxicol 2013;112:222-228.
16.
Bayne K: Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society. Physiologist 1996;39:199, 208-211.
17.
Aghazadeh-Habashi A, Sattari S, Pasutto FM, Jamali F: Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci 2002;5:181-184.
18.
Ordóñez M, De la Cruz R, Fernández-Zertuche M, Muñoz-Hernández M: Diastereoselective reduction of β-ketophosphonates derived from amino acids. A new entry to enantiopure β-hydroxy-γ-aminophosphonate derivatives. Tetrahedron Asymmetry 2002;13:559-562.
19.
Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, Benatti P, Calvani M: Carnitine: an osmolyte that plays a metabolic role. J Cell Biochem 2000;80:1-10.
20.
Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W: Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res 2001;51:21-29.
21.
Evans AM, Fornasini G: Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003;42:941-967.
22.
Brain MA, Milne RW, Evans AM: Disposition and metabolite kinetics of oral L-carnitine in humans. J Clin Pharmacol 2006;46:1163-1170.
23.
Fischer M, Varady J, Hirche F, Kluge H, Eder K: Supplementation of L-carnitine in pigs: absorption of carnitine and effect on plasma and tissue carnitine concentrations. Arch Anim Nutr 2009;63:1-15.
24.
Toutain PL, Ferran A, Bousquet-Mélou A: Species differences in pharmacokinetics and pharmacodynamics; in Cunningham F, et al (eds): Comparative and Veterinary Pharmacology: Handbook of Experimental Pharmacology. Berlin, Springer, 2010, pp 19-48.
25.
Mahmood I: Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockeville, Pine House, 2005.
26.
Kasiske BL, O'Donnell MP, Keane WF: The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992;19:110-115.
27.
Iannitti T, Graham A, Dolan S: Increased central and peripheral inflammation and inflammatory hyperalgesia in Zucker rat model of leptin receptor deficiency and genetic obesity. Exp Physiol 2012;97:1236-1245.
28.
Iliescu R, Chade AR: Progressive renal vascular proliferation and injury in obese Zucker rats. Microcirculation 2010;17:250-258.
29.
Yamaguchi T, Miyashita Y, Saiki A, Watanabe F, Watanabe H, Shirai K: Formula diet is effective for the reduction and differentiation of visceral adipose tissue in Zucker fatty rats. J Atheroscler Thromb 2012;19:127-136.
30.
Toblli JE, Muñoz MC, Cao G, Mella J, Pereyra L, Mastai R: ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008;16:770-776.
31.
Laurent D, Gounarides JS, Gao J, Boettcher BR: Effects of cevoglitazar, a dual PPARα/γ agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes Metab 2009;11:632-636.
32.
Kalderon B, Mayorek N, Ben-Yaacov L, Bar-Tana J: Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo. Am J Physiol Endocrinol Metab 2003;284:E795-E803.
33.
Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F: L-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am J Gastroenterol 2010;105:1338-1345.
34.
Xia Y, Li Q, Zhong W, Dong J, Wang Z, Wang C: L-Carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndr 2011;3:31.
35.
Yokoi N, Hoshino M, Hidaka S, Yoshida E, Beppu M, Hoshikawa R, Sudo K, Kawada A, Takagi S, Seino S: A novel rat model of type 2 diabetes: the Zucker fatty diabetes mellitus ZFDM rat. J Diabetes Res 2013;2013:103731.
36.
Cha YS: Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. Asia Pac J Clin Nutr 2008;17(suppl 1):306-308.
37.
García AP, Horack GC: Sibutramina/carnitina muestra eficacia en la reducción de peso en pacientes con obesidad y sobrepeso. Rev Endocrinol Nutr 2008;16:153-157.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.